Protara Therapeutics (TARA) Competitors $4.96 +0.74 (+17.54%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$5.01 +0.05 (+1.01%) As of 09:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TARA vs. OLMA, KROS, BCAX, KALV, GOSS, SNDL, SVRA, ARVN, MBX, and ARCTShould you be buying Protara Therapeutics stock or one of its competitors? The main competitors of Protara Therapeutics include Olema Pharmaceuticals (OLMA), Keros Therapeutics (KROS), Bicara Therapeutics (BCAX), KalVista Pharmaceuticals (KALV), Gossamer Bio (GOSS), SNDL (SNDL), Savara (SVRA), Arvinas (ARVN), MBX Biosciences (MBX), and Arcturus Therapeutics (ARCT). These companies are all part of the "pharmaceutical products" industry. Protara Therapeutics vs. Its Competitors Olema Pharmaceuticals Keros Therapeutics Bicara Therapeutics KalVista Pharmaceuticals Gossamer Bio SNDL Savara Arvinas MBX Biosciences Arcturus Therapeutics Protara Therapeutics (NASDAQ:TARA) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership. Which has preferable valuation & earnings, TARA or OLMA? Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtara TherapeuticsN/AN/A-$44.60M-$1.62-3.06Olema PharmaceuticalsN/AN/A-$129.47M-$1.98-5.61 Which has more volatility and risk, TARA or OLMA? Protara Therapeutics has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, Olema Pharmaceuticals has a beta of 2.08, suggesting that its share price is 108% more volatile than the S&P 500. Is TARA or OLMA more profitable? Protara Therapeutics' return on equity of -36.87% beat Olema Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Protara TherapeuticsN/A -36.87% -33.85% Olema Pharmaceuticals N/A -42.58%-38.65% Does the media prefer TARA or OLMA? In the previous week, Olema Pharmaceuticals had 3 more articles in the media than Protara Therapeutics. MarketBeat recorded 4 mentions for Olema Pharmaceuticals and 1 mentions for Protara Therapeutics. Olema Pharmaceuticals' average media sentiment score of 0.93 beat Protara Therapeutics' score of 0.00 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Olema Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer TARA or OLMA? Protara Therapeutics currently has a consensus price target of $19.60, suggesting a potential upside of 295.16%. Olema Pharmaceuticals has a consensus price target of $24.00, suggesting a potential upside of 116.22%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Protara Therapeutics is more favorable than Olema Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protara Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86Olema Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Do insiders & institutionals hold more shares of TARA or OLMA? 38.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 12.5% of Protara Therapeutics shares are held by company insiders. Comparatively, 16.4% of Olema Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryProtara Therapeutics beats Olema Pharmaceuticals on 8 of the 13 factors compared between the two stocks. Get Protara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TARA vs. The Competition Export to ExcelMetricProtara TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$191.36M$2.62B$6.11B$10.54BDividend YieldN/A56.38%5.66%4.70%P/E Ratio-3.0624.2286.8126.71Price / SalesN/A530.20538.97202.98Price / CashN/A28.3526.3031.09Price / Book1.045.3112.676.57Net Income-$44.60M$32.78M$3.30B$276.78M7 Day Performance12.47%2.70%3.55%1.96%1 Month Performance57.46%8.77%6.79%9.11%1 Year Performance177.09%-3.79%72.30%31.60% Protara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TARAProtara Therapeutics1.7443 of 5 stars$4.96+17.5%$19.60+295.2%+177.1%$191.36MN/A-3.0630Gap UpOLMAOlema Pharmaceuticals2.8804 of 5 stars$9.54+0.3%$24.00+151.6%-4.3%$652.71MN/A-4.8270KROSKeros Therapeutics2.1164 of 5 stars$15.95-0.6%$30.00+88.1%-73.8%$651.88M$3.55M51.45100BCAXBicara Therapeutics2.3308 of 5 stars$13.87+18.4%$32.25+132.5%-32.3%$638.93MN/A-4.3832High Trading VolumeKALVKalVista Pharmaceuticals3.9139 of 5 stars$12.21-1.5%$26.43+116.5%+4.3%$626.49MN/A-3.10100GOSSGossamer Bio4.0142 of 5 stars$2.82+4.4%$8.50+201.4%+140.2%$613.93M$114.70M-4.55180SNDLSNDL3.3592 of 5 stars$2.74+17.6%$4.50+64.2%+29.0%$612.27M$671.81M-10.152,516Analyst DowngradeHigh Trading VolumeSVRASavara2.7597 of 5 stars$3.52flat$7.50+113.1%-8.6%$608.39MN/A-7.0420Trending NewsARVNArvinas3.099 of 5 stars$8.53+3.1%$16.18+89.7%-61.5%$607.16M$263.40M-8.45420MBXMBX Biosciences3.6372 of 5 stars$17.94+2.5%$39.88+122.3%-29.7%$602.68MN/A-3.9536ARCTArcturus Therapeutics2.611 of 5 stars$18.78-15.3%$50.57+169.3%-5.5%$602.02M$152.31M-8.42180High Trading Volume Related Companies and Tools Related Companies OLMA Alternatives KROS Alternatives BCAX Alternatives KALV Alternatives GOSS Alternatives SNDL Alternatives SVRA Alternatives ARVN Alternatives MBX Alternatives ARCT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TARA) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
